Stocks · News reference

Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.

Sep 4, 2026, 8:34 PMBenzinga News-desk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 4, 2026, 8:32 PMBenzinga News-desk
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of
Read original at benzinga
IONS NVS
BenzingaSep 4, 2026, 3:33 PMVandana Singh
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
Read original at benzinga
BMY NVS
Zacks Investment ResearchSep 2, 2026, 6:29 PMZacks.Com
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.
Read original at zacks-investment-research
NVS RGEN ANIK